New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
Read moreMRC Translational Immune Discovery Unit
Pioneering the future in the study of human immunity to uncover the molecular pathways driving immune-mediated diseases.
MRC Molecular Haematology Unit
Understanding how mature blood cells are normally made from stem cells and how this is perturbed in common blood disorders.
Centre for Computational Biology
Using computational biology to help understand complex biological systems and combat a range of human diseases.
Latest publications
-
Iron deficiency causes aspartate-sensitive dysfunction in CD8+ T cells.
Journal article
Teh MR. et al, (2025), Nat Commun, 16
-
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.
Journal article
Brierley CK. et al, (2025), Nat Genet
-
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study
Journal article
Hughes SE. et al, (2025), Eclinicalmedicine, 84
-
Oxford Classic-defined EMT risk stratification of High Grade Serous Ovarian cancer for guiding treatment decisions
Journal article
AHMED A., (2025), Clinical Cancer Research
-
Immune perturbation by the ileal microbiota in multiple sclerosis.
Journal article
Jensen LT. and Fugger L., (2025), Proc Natl Acad Sci U S A, 122
Upcoming Seminars
-
Friday, 27 June 2025, 9.15am to 10.15am
Speakers: Sofia Bustamante Eguiguren
-
Friday, 04 July 2025, 9.15am to 10.15am
Speakers: Shamsideen Yusuf, Dana Costigan
-
Monday, 07 July 2025, 1pm to 2pm
Speakers: Professor Christian Kastrup
-
Tuesday, 15 July 2025, 1pm to 2pm
Speakers: Professor Bertie Gottgens
-
Tuesday, 02 September 2025, 1pm to 2pm
Speakers: Dr Arno Alpi